Walvax Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Walvax Biotechnology kazanç ve gelirin sırasıyla yıllık 54.6% ve 11.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 54.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 6.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

54.6%

Kazanç büyüme oranı

54.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.4%
Gelir büyüme oranı	11.7%
Gelecekteki özkaynak getirisi	6.1%
Analist kapsamı	Low
Son güncelleme	29 Oct 2024

Gelecekteki son büyüme güncellemeleri

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Recent updates

We Think Walvax Biotechnology (SZSE:300142) Can Stay On Top Of Its Debt

Nov 25

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Sep 24

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300142 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,961	788	N/A	851	2
12/31/2025	3,605	646	N/A	1,006	2
12/31/2024	3,114	399	N/A	1,178	2
9/30/2024	3,097	122	163	832	N/A
6/30/2024	3,379	135	52	839	N/A
3/31/2024	3,880	262	5	855	N/A
12/31/2023	4,114	419	188	1,134	N/A
9/30/2023	4,538	751	214	1,191	N/A
6/30/2023	4,906	763	158	1,185	N/A
3/31/2023	5,264	862	218	1,395	N/A
1/1/2023	5,086	729	110	1,201	N/A
9/30/2022	5,040	595	160	1,311	N/A
6/30/2022	4,461	530	-84	1,118	N/A
3/31/2022	3,685	434	-263	856	N/A
1/1/2022	3,463	428	-398	705	N/A
9/30/2021	3,501	932	-660	267	N/A
6/30/2021	3,715	1,261	-525	139	N/A
3/31/2021	3,260	1,053	-452	26	N/A
12/31/2020	2,939	1,003	-293	114	N/A
9/30/2020	1,890	457	-275	120	N/A
6/30/2020	1,194	119	-303	84	N/A
3/31/2020	1,057	85	-343	13	N/A
12/31/2019	1,121	142	-290	62	N/A
9/30/2019	1,098	1,444	-241	72	N/A
6/30/2019	1,000	1,426	-327	-44	N/A
3/31/2019	933	1,430	-265	-13	N/A
12/31/2018	874	1,415	-293	-65	N/A
9/30/2018	807	-407	-307	-81	N/A
6/30/2018	786	-421	N/A	-62	N/A
3/31/2018	700	-484	N/A	-14	N/A
12/31/2017	668	-537	N/A	-10	N/A
9/30/2017	628	265	N/A	70	N/A
6/30/2017	555	189	N/A	55	N/A
3/31/2017	466	83	N/A	-33	N/A
12/31/2016	591	70	N/A	-90	N/A
9/30/2016	692	-963	N/A	-153	N/A
6/30/2016	885	-936	N/A	-169	N/A
3/31/2016	1,045	-835	N/A	-133	N/A
12/31/2015	1,006	-841	N/A	-69	N/A
9/30/2015	843	182	N/A	-44	N/A
6/30/2015	731	138	N/A	-73	N/A
3/31/2015	705	147	N/A	-16	N/A
12/31/2014	719	143	N/A	-66	N/A
9/30/2014	816	-139	N/A	-149	N/A
6/30/2014	750	-91	N/A	-159	N/A
3/31/2014	676	-29	N/A	-149	N/A
12/31/2013	583	48	N/A	-122	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300142 'nin tahmini kazanç büyümesi (yıllık 54.6% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 300142 şirketinin kazançlarının (yıllık 54.6% ) CN pazarından (yıllık 26.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300142 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 300142 şirketinin gelirinin (yıllık 11.7% ) CN pazarından (yıllık 13.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300142 şirketinin gelirinin (yıllık 11.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300142 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 6.1 %).

Walvax Biotechnology Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 11%

Price target decreased by 28% to CN¥13.00

Consensus revenue estimates fall by 16%

Price target decreased by 11% to CN¥17.00

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

We Think Walvax Biotechnology (SZSE:300142) Can Stay On Top Of Its Debt

Consensus revenue estimates fall by 11%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Walvax Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Price target decreased by 28% to CN¥13.00

Consensus revenue estimates fall by 16%

Price target decreased by 11% to CN¥17.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

First quarter 2024 earnings: EPS and revenues miss analyst expectations

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Consensus revenue estimates fall by 12%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Price target decreased by 25% to CN¥25.50

Consensus revenue estimates fall by 21%

Price target decreased by 8.1% to CN¥34.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Price target increased by 19% to CN¥37.00

Price target decreased by 9.1% to CN¥30.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 16%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥32.00

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥36.00

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Consensus forecasts updated

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥48.62

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

Earnings released

New 90-day high - CN¥71.98

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi